The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
Using data visualizations to improve access to payers.
As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.
New technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.
It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.
With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Organ-on-a-Chip technology has been proven to predict DILI with a higher rate of confidence than traditional in vitro methods and animals. Start protecting human health today.
Delivering on the mission of personalized patient support
The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.
Merging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.
Industry stakeholders must come together to make meaningful changes to reimbursement and establish comprehensive policies that support essential healthcare providers.
When approached correctly, drug development in the rare disease space can be quite successful – especially when powerhouses across the industry join forces and leverage the power of data to help drive potential treatment options.
New C-Suite position emerges for more emphasis on patient centricity.
Biopharma companies and contract research organizations (CROs) adopted decentralized or digital clinical trials (DCTs) to reduce contact, improve the patient experience and keep studies on track during the pandemic. It’s already clear that the virtual approach of DCTs are benefiting life science organizations. From improvements in clinical trial operations such as enhanced patient engagement and site experience to cost savings and better data integration, the clinical trial dynamic has shifted and supports DCTs as a legitimate way to execute studies.
Common advice for OA sufferers is joint replacement, but other options are on the horizon.
In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.
What the Changing Healthcare Landscape Demands of Future MA Professionals?
Paige Bingham has focused her career on improving clinical research operations and logistics, and not just ways to ease the burden for investigators and teams running the trials—but also for the patients involved in them.
Storytelling can be used very effectively to communicate with medical professionals without compromising the science, writes Stacey Rivkin.
Biopharma must step up amidst growing oncology market.
How companies are leveraging Real Word Evidence to evaluate therapies under real world conditions in a broader population at a lower cost than using Randomized Clinical Trials.
Understanding of recent legal developments can help companies avoid infringement.
Their integration across enterprise remains pivotal driver for success.
In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.
The era of big pharma as product-first companies must end, as services become the larger priority.
In an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.
Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.
In the rapidly changing fields of medicine, such as hematology/oncology and specifically with respect to the management of patients with chronic lymphocytic leukemia (CLL), education is a key component of keeping clinicians current on changes to treatment paradigms.
Companies must determine the right ways to utilize AI.